• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝硬化经 SVR 后通过间接纤维化分析方法得到逆转:这一目标有多现实?

Cirrhosis regression after SVR with indirect methods of fibrosis analysis: How far is it real?

机构信息

Department of Clinical Medicine, Botucatu Medical School, São Paulo State University (UNESP), Av. Prof. Mário Rubens Guimarães Montenegro, s/n - UNESP, Botucatu, São Paulo, Brazil.

Undergraduate Course in Medicine, Taubaté Medical School - UNITAU, Taubaté, São Paulo, Brazil.

出版信息

Clin Exp Med. 2022 May;22(2):269-275. doi: 10.1007/s10238-021-00749-1. Epub 2021 Aug 4.

DOI:10.1007/s10238-021-00749-1
PMID:34347205
Abstract

Hepatitis C virus has infected over 71 million people worldwide, and it is the main cause of cirrhosis in the western world. Currently, the treatment involves direct-acting antiviral agents (DAAs) and its main goal is to achieve sustained virologic response (SVR). The aim of this study was to evaluate the impact of SVR using DAAs in the improvement of liver fibrosis using scores evaluation by indirect method, liver function, and inflammation indirect biomarkers. Patients with cirrhosis with SVR after treatment (n = 104) were evaluated using liver function scores, indirect fibrosis methods, alpha-fetoprotein, and ferritin at t-base and t-SVR. Statistically significant positive results in all parameters were observed: 54 patients were classified as 5 in the CP score in t-base, and 77 in t-SVR; a significant decrease was observed in MELD score, alpha-fetoprotein, ferritin, APRI, FIB-4 and liver stiffness in liver elastography. We did not observe difference in the liver function scores between regressors and non-regressors of liver stiffness, as well as in indirect inflammation biomarkers. The measurements of fibrosis using the indirect methods have significantly decreased in patients with cirrhosis treated who achieved SVR associated with decreased indirect inflammation biomarkers and improved liver function scores.

摘要

丙型肝炎病毒已感染全球超过 7100 万人,是西方世界肝硬化的主要病因。目前,治疗方法包括直接作用抗病毒药物(DAA),其主要目标是实现持续病毒学应答(SVR)。本研究旨在通过间接方法的评分评估、肝功能和炎症间接标志物,评估 DAA 治疗后 SVR 对肝纤维化的改善情况。我们评估了治疗后 SVR 的肝硬化患者(n=104)的肝功能评分、间接纤维化方法、甲胎蛋白和铁蛋白在 t 基础和 t-SVR 时的水平。所有参数均观察到有统计学意义的阳性结果:54 例患者在 t 基础时 CP 评分中被分类为 5 分,而在 t-SVR 时为 77 分;MELD 评分、甲胎蛋白、铁蛋白、APRI、FIB-4 和肝脏弹性成像中的肝硬度显著降低。我们未观察到肝硬度的回归与非回归患者之间的肝功能评分以及间接炎症标志物之间存在差异。用间接方法测量的纤维化在实现 SVR 的肝硬化患者中显著降低,与间接炎症标志物降低和肝功能评分改善有关。

相似文献

1
Cirrhosis regression after SVR with indirect methods of fibrosis analysis: How far is it real?肝硬化经 SVR 后通过间接纤维化分析方法得到逆转:这一目标有多现实?
Clin Exp Med. 2022 May;22(2):269-275. doi: 10.1007/s10238-021-00749-1. Epub 2021 Aug 4.
2
Noninvasive Measurements Predict Liver Fibrosis Well in Hepatitis C Virus Patients After Direct-Acting Antiviral Therapy.直接作用抗病毒治疗后,非侵入性测量可很好地预测丙型肝炎病毒患者的肝纤维化。
Dig Dis Sci. 2020 May;65(5):1491-1500. doi: 10.1007/s10620-019-05886-y. Epub 2019 Oct 25.
3
Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index.直接抗病毒药物治疗慢性丙型肝炎可导致瞬时弹性成像和纤维化标志物 4 分(fibrosis-4 score)及天冬氨酸氨基转移酶-血小板比值指数(aspartate aminotransferase-platelet ratio index)迅速改善。
Liver Int. 2017 Mar;37(3):369-376. doi: 10.1111/liv.13256. Epub 2016 Nov 3.
4
α-fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response.干扰素治疗后甲胎蛋白水平可预测病毒学持续应答患者肝纤维化的消退情况。
J Gastroenterol Hepatol. 2016 May;31(5):1001-8. doi: 10.1111/jgh.13245.
5
Long-term clinical outcomes in sustained responders with chronic hepatitis C after treatment with direct-acting antivirals.直接作用抗病毒药物治疗慢性丙型肝炎持续应答者的长期临床结局。
Eur J Gastroenterol Hepatol. 2021 Dec 1;33(1S Suppl 1):e746-e752. doi: 10.1097/MEG.0000000000002240.
6
Liver Stiffness at the Time of Sustained Virological Response Predicts the Clinical Outcome in People Living With Human Immunodeficiency Virus and Hepatitis C Virus With Advanced Fibrosis Treated With Direct-acting Antivirals.在直接作用抗病毒药物治疗下,患有晚期纤维化的人类免疫缺陷病毒和丙型肝炎病毒感染者,在持续病毒学应答时的肝硬度可预测临床结局。
Clin Infect Dis. 2020 Dec 3;71(9):2354-2362. doi: 10.1093/cid/ciz1140.
7
M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals.M2BPGi 用于评估丙型肝炎直接作用抗病毒药物治疗患者的肝纤维化。
World J Gastroenterol. 2020 Jun 7;26(21):2864-2876. doi: 10.3748/wjg.v26.i21.2864.
8
Noninvasive Assessment of Fibrosis Regression after Direct-acting Antiviral Treatment in Hepatitis C Virus Patients.直接作用抗病毒治疗后丙型肝炎病毒患者纤维化消退的无创评估。
Isr Med Assoc J. 2021 Dec;23(12):794-800.
9
Glycomics-based serum markers as reliable tool for assessment of viral response after treatment with direct-acting antiviral drugs in hepatitis C virus infection.基于糖组学的血清标志物可作为丙型肝炎病毒感染患者应用直接作用抗病毒药物治疗后病毒应答评估的可靠工具。
Acta Clin Belg. 2023 Apr;78(2):96-102. doi: 10.1080/17843286.2022.2072110. Epub 2022 May 3.
10
Direct antiviral agent treatment leads to rapid and significant fibrosis regression after HCV eradication.直接抗病毒药物治疗可在 HCV 清除后迅速显著地逆转肝纤维化。
J Viral Hepat. 2021 Sep;28(9):1284-1292. doi: 10.1111/jvh.13558. Epub 2021 Jun 20.

引用本文的文献

1
Short-term hepatocyte function and portal hypertension outcomes of sofosbuvir/velpatasvir for decompensated hepatitis C-related cirrhosis.索磷布韦/维帕他韦治疗失代偿期丙型肝炎相关肝硬化的短期肝细胞功能和门脉高压结局。
J Gastroenterol. 2023 Apr;58(4):394-404. doi: 10.1007/s00535-023-01963-2. Epub 2023 Feb 2.

本文引用的文献

1
Postsustained Virological Response Management in Hepatitis C Patients.慢性丙型肝炎患者持续病毒学应答的管理。
Semin Liver Dis. 2020 Aug;40(3):233-239. doi: 10.1055/s-0040-1702944. Epub 2020 Feb 27.
2
Rapid decline of noninvasive fibrosis index values in patients with hepatitis C receiving treatment with direct-acting antiviral agents.接受直接抗病毒药物治疗的丙型肝炎患者非侵入性纤维化指数值迅速下降。
BMC Gastroenterol. 2019 Apr 27;19(1):63. doi: 10.1186/s12876-019-0973-5.
3
Morphometry Confirms Fibrosis Regression From Sustained Virologic Response to Direct-Acting Antivirals for Hepatitis C.
形态测量学证实丙型肝炎患者经直接抗病毒药物治疗获得持续病毒学应答后纤维化消退
Hepatol Commun. 2018 Sep 21;2(11):1320-1330. doi: 10.1002/hep4.1228. eCollection 2018 Nov.
4
Clinical states of cirrhosis and competing risks.肝硬化的临床状态和竞争风险。
J Hepatol. 2018 Mar;68(3):563-576. doi: 10.1016/j.jhep.2017.10.020. Epub 2017 Oct 27.
5
Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience.在格鲁吉亚国家丙型肝炎消除计划中接受治疗的慢性丙型肝炎患者完成直接抗病毒治疗后24周内肝纤维化的消退情况:肝病诊所HEPA经验的结果
Eur J Gastroenterol Hepatol. 2017 Nov;29(11):1223-1230. doi: 10.1097/MEG.0000000000000964.
6
Decrease of Alpha-fetoprotein in Patients with Cirrhosis Treated with Direct-acting Antivirals.接受直接抗病毒药物治疗的肝硬化患者甲胎蛋白水平的降低
J Clin Transl Hepatol. 2017 Mar 28;5(1):43-49. doi: 10.14218/JCTH.2016.00057. Epub 2017 Mar 8.
7
Magnitude and Kinetics of Decrease in Liver Stiffness After Antiviral Therapy in Patients With Chronic Hepatitis C: A Systematic Review and Meta-analysis.抗病毒治疗后慢性丙型肝炎患者肝硬度下降幅度和速度的系统评价和荟萃分析。
Clin Gastroenterol Hepatol. 2018 Jan;16(1):27-38.e4. doi: 10.1016/j.cgh.2017.04.038. Epub 2017 May 4.
8
American Gastroenterological Association Institute Guideline on the Role of Elastography in the Evaluation of Liver Fibrosis.美国胃肠病学会关于弹性成像在肝纤维化评估中作用的指南
Gastroenterology. 2017 May;152(6):1536-1543. doi: 10.1053/j.gastro.2017.03.017.
9
Accuracy of the ElastPQ Technique for the Assessment of Liver Fibrosis in Patients with Chronic Hepatitis C: a "Real Life" Single Center Study.ElastPQ 技术评估慢性丙型肝炎患者肝纤维化的准确性:一项“真实世界”单中心研究。
J Gastrointestin Liver Dis. 2016 Sep;25(3):331-5. doi: 10.15403/jgld.2014.1121.253.epq.
10
Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications.肝硬化患者清除丙型肝炎病毒感染可降低肝脏和非肝脏并发症的风险。
Gastroenterology. 2017 Jan;152(1):142-156.e2. doi: 10.1053/j.gastro.2016.09.009. Epub 2016 Sep 15.